Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

ASCO® GU 2024
22:03

Dana-Farber Cancer Institute

RCC Highlights From ASCO® GU 2024

FEATURING Wenxin Xu, Toni Choueiri
  • 130 views
  • March 14, 2024
  • 1
02:31

Dana-Farber Cancer Institute

Testicular Cancer Highlights From ASCO® GU 2024

FEATURING Alok Tewari
  • 102 views
  • March 14, 2024
22:58

Dana-Farber Cancer Institute

Bladder Cancer Highlights From ASCO® GU 2024

FEATURING Charlene Mantia, Joaquim Bellmunt
  • 104 views
  • March 13, 2024
  • 1
23:03

Dana-Farber Cancer Institute

Prostate Cancer Highlights From ASCO® GU 2024

FEATURING Jacob Berchuck, Atish Choudhury
  • 157 views
  • March 13, 2024
02:23

Dana-Farber Cancer Institute

ASCO® GU 2024 Insights: "Association of DAZL Expression With Risk of Recurrence in Clinical Stage 1 Testicular Germ Cell Tumors"

FEATURING Alok Tewari
  • 28 views
  • February 20, 2024
02:31

Dana-Farber Cancer Institute

ASCO® GU 2024 Insights: "Rate of Hospitalization and Length of Hospital Stay During and Post Docetaxel for Darolutamide in mHSPC Using ARASENS"

FEATURING Alicia Morgans
  • 12 views
  • February 20, 2024
02:35

Dana-Farber Cancer Institute

ASCO® GU 2024 Insights: "OS Results From the KEYNOTE-564 Study - Adjuvant Pembro vs. Placebo for the Treatment of ccRCC"

FEATURING Toni Choueiri
  • 52 views
  • February 20, 2024
02:38

Dana-Farber Cancer Institute

ASCO® GU 2024 Insights: "Impact of Race on Outcomes to 177Lu-PSMA-617 for mCRPC"

FEATURING Avina Rami
  • 17 views
  • February 20, 2024
02:22

Dana-Farber Cancer Institute

ASCO® GU 2024 Insights: "Patient Characteristics, Treatment Patterns, and Outcomes Among Early Adopters of 177Lu-PSMA-617 for Prostate Cancer"

FEATURING Xiao Wei
  • 31 views
  • February 20, 2024